Enigma Diagnostics Announces Successful Evaluation of the Enigma FL by the UK's Veterinary...

Enigma Diagnostics Announces Successful Evaluation of the Enigma FL by the
UK's Veterinary Laboratories Agency

PORTON DOWN, England, June 30 /PRNewswire/ -- Enigma Diagnostics Limited, the
decentralised and point-of-care molecular diagnostics company, announced today
successful independent testing for bovine viral diarrhoea (BVD) by the
Veterinary Laboratories Agency to evaluate the performance of the Enigma FL
(Field Laboratory).

BVD is considered to be one of the main threats to cattle (1), affecting the
majority of herds in the UK. It is closely related to classical swine fever
virus, a serious disease of pigs, and to border disease virus, which infects
sheep.

The Enigma FL instrument was used to analyse more than 100 blood samples that
had already been screened by antigen ELISA and a laboratory-based RT-PCR for
the presence of the BVD virus. Approximately half of the samples were proved
BVDV positive by the laboratory-based PCR. With the level of concordance
between the two tests being above 97%, this confirmed the Enigma FL system can
produce laboratory-standard results with a high degree of confidence.

The Enigma FL has been designed for easy operation. Tests are provided in a
single-use cartridge that can be stored at room temperature. The Enigma FL
provides a PCR result in less than one hour, a timescale needed to allow
field-based & pen-side diagnosis. On-site testing removes delays from
transport of samples to the laboratory, which can often take days. The system
requires minimal training and its utility for "pen-side" testing for BVD has
already been demonstrated.(2)

John McKinley, Chairman and CEO of Enigma, stated: "The Enigma Diagnostics
tests could be deployed for the related viral diseases, such as classical
swine fever, with minor modifications. The system itself is broadly
applicable to many other veterinary pathogens, such as TB in cattle, bacterial
infections and other viral infections, such as foot and mouth disease and
avian influenza. Allowing vets to use advanced molecular diagnosis in the
field will enhance their efficiency in managing endemic and exotic disease
outbreaks identifying diseased animals and as importantly, non-infected ones
and improve their surveillance capability."

(1) http://www.rvc.ac.uk/BVD/documents/BVD_Disease.ppt
(2) http://enigmadiagnostics.com/template2.php?page=news.php&m=4

Contacts

UK Contact:
Enigma Diagnostics
Deborah Cordingley
deborah.cordingley@enigmadiagnostics.com
+44 1980 590131

US Contact:
Richard Lewis Communications, Inc.
212-827-0020
Gregory Tiberend - Media
gtiberend@rlcinc.com
Cecelia Heer - Investors
cheer@rlcinc.com

About Enigma Diagnostics Limited

Enigma Diagnostics Limited is a private UK based company specialising in
developing the next generation of rapid molecular diagnostic instrument
platforms for decentralised and point-of-care settings.

Enigma's innovative and proprietary technology combines the speed and
sensitivity of real-time PCR (polymerase chain reaction) with the simplicity
needed for field-based, decentralised and point-of-care tests providing
results from a raw sample in less than 45 minutes.

The Company is targeting a number of multi-billion pound markets, core among
which are the Clinical and high value Applied Markets. Enigma's
commercialisation strategy is to maximise revenues from a continuous flow of
market leading rapid diagnostic point-of care and in-field instrument and
assay platforms, derived from its broad Intellectual Property portfolio of
issued and filed patents. Enigma will partner with market leaders where global
penetration of markets is required and where appropriate will build an
in-house sales and marketing capability to direct distribution of its
products.

Enigma has an exclusive licence from the Defence Science and Technology
Laboratory to a portfolio of patents, which represent over 15 years of UK
Ministry of Defence funded research and has licences from Applied Biosystems
and Celera Licences for the commercialisation of real-time PCR instruments.
Enigma's R&D activities have generated a portfolio of over 50 plus worldwide
patent families dedicated to real-time PCR and wider molecular technologies.
Many of these patents are granted across a range of core commercial
territories including US, EU and Japan with more extensive filing and grants
across a number of other key territories.

For more information visit www.enigmadiagnostics.com.

SOURCE Enigma Diagnostics Limited

UK Contact: Deborah Cordingley, +44-1980-590131, or
deborah.cordingley@enigmadiagnostics.com of Enigma Diagnostics; US Contact:
Gregory Tiberend - Media, gtiberend@rlcinc.com, or Cecelia Heer - Investors,
cheer@rlcinc.com, both of Richard Lewis Communications, Inc., +1-212-827-0020,
for Enigma Diagnostics